• PlantX offers consumers personal care plant-based products across Bath and Body, Skincare, Vitamins & Dietary Supplements
• Vegan personal care on the rise; 59% of Gen Y and Z consumers prefer more environmentally-friendly cosmetic products
• The company committed to further growth in the plant-based personal care product category; enters into a strategic partnership with Nootka & Sea, a premier plant-based apothecary, and cosmetics company

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) continues to be committed to a plant-based lifestyle that it believes goes beyond just a diet and includes an opportunity to unite with nature and people around a kinder and cruelty-free future for everyone. This effort includes personal care plant-based beauty products across the company’s Bath and Body, Skincare, Vitamins & Dietary Supplements categories (https://ibn.fm/kyNKd). Bath and Body range includes Body Care, Deodorant, Facial Care, Hair Care, Oral Care, and Soaps & Sanitizers, offering consumers a possibility to care for their personal health and hygiene with products that are based on nourishing, natural ingredients that are less likely to lead to irritation while also ensuring that their production involved cruelty-free processes. With its Skincare product line spanning across Cleansers, Creams, and Serums, PlantX allows plant-focused consumers to give their skin the attention it deserves. The company enables them to adopt a complete skincare routine that supports their skin integrity, alleviates skin conditions, and enhances their appearance. The Vitamins & Dietary Supplements provides what is believed to build health from within — from Vitamins & Minerals, Multivitamins, Probiotics, Protein Sports Nutrition to Superfoods & Greens and Detox & Cleanse products. Committed to growing beyond a marketplace for plant-based products to build a whole plant-based ecosystem and become the most trusted, one-stop destination for people living plant-based lives, PlantX has entered into a strategic partnership with Nootka & Sea, a privately held British Columbia company that operates in the apothecary and cosmetics space. The partnership will allow PlantX to include NOOTKA’s products in the Beauty section of the company’s Canadian and U.S. e-commerce platforms. The company is confident that NOOTKA’s s brand portfolio fits perfectly with what PlantX stands for in the market (https://ibn.fm/KxsJv). “We are aiming to be the digital face of the plant-based community, and as such, we want to be able to carry and offer the very highest-quality products for our customers,” said Sean Dollinger, PlantX founder. “This partnership will help us capitalize on this exciting market.” The NOOTKA has a retail location near the new PlantX flagship brick-and-mortar store in Squamish, British Columbia, where it sells high-quality plant-based apothecary, self-care and wellness, and low waste products. These include essential oils and diffusers; skincare and oral care items, men’s grooming products, such as beard care and scalp tonic; home goods; and curated gift boxes. “Having a brand and location situated close to our new Canadian flagship store is so exciting,” stated Julia Frank, PlantX CEO. “With our distribution and resources as an e-commerce site, we believe we can turn this into one of our largest verticals.” PlantX appears to prove again that it is quick to recognize and act upon emerging market trends. Vegan cosmetics is a market segment with significant growth potential and could be a great opportunity for competitive differentiation. Statistics show that 59% of Gen Y and Z consumers prefer more environmentally-friendly cosmetic products (https://ibn.fm/6zHKH). Vegan beauty may become a standard for cosmetic product consumption in the future as consumers increasingly value naturalness which is the second driver of purchase, second only to the product’s effectiveness. As consumers worldwide are becoming more health and environmentally aware, and better informed about the benefits of the plant-based lifestyle, PlantX is poised to capitalize on opportunities across the whole ecosystem it resolutely aims to build. With its well-rounded business model that leverages both e-commerce platform and premium brick and mortar presence, PlantX appears well-placed to maintain its leading position as the high growth company centered around a plant-based lifestyle. For more information, visit the company’s website at www.Investor.PlantX.com, and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Company files 12th patent to strengthen proprietary IP program
• Cybin believes treatments can decrease costs, increase access to important therapeutics
• Patent provides wide range of benefits in Cybin’s four drug candidate program

Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules.

“By continuing to innovate in directions to enhance the patient experience and reducing clinical observation times, we believe our treatments can decrease costs and increase the capacity of medical professionals in this field, which will promote increased access to these important therapeutics for those in need,” said Cybin CEO Doug Drysdale.

According to the announcement, the patent — the 12th filed by the company— has a provisional application including disclosures directed to innovate oral dosage forms thought to provide therapeutic advantages in addressing Cybin’s target indications over the current options. The application is also synergistic with other patent applications filed by Cybin that are also related to a delivery technology covering various chemically synthesized psychedelic molecules, which is expected to provide faster onset times in a similar route to intravenous treatments.

In addition, Cybin noted that the patent application strengthens its portfolio relative to deuterated psychedelic molecules and analogues that are designed to produce greater stability, better potency, more control over duration and greater bioavailability than other forms of these molecules. Finally, the patent application disclosures related to more rapid therapeutic onset as well as reduced duration and side effects are intended to decrease the clinical costs of administration resulting from shortened clinical observation time.

Cybin filed the patent with the U.S. Food and Drug Administration, an application that reveals novel compositions intended to have improved pharmacokinetic profiles while retaining key efficacy measures of the original molecules; the application also outlines novel methods of deploying Cybin’s original compositions with more rapid therapeutic onset of the company’s psychedelic tryptamine at the same time while reducing the number and duration of psychedelic and therapeutic effects.

Cybin’s four drug programs include CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamine designed for treatment of alcohol use disorder and other therapy resistant psychiatric disorders; and CYB005, a phenethylamine targeting psychiatry and neurology treatment.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• FingerMotion generates revenue from its SMS and MMS business and its Telecommunication Products & Services (“TPS”) division
• FNGR is guided by innovation and has always sought to increase value for its clients by continually improving its SMS and PigeonHoles Integration System (“PIS”) platforms
• The company has differentiated its TPS division by creating a platform capable of handling thousands of transactions per minute with a 99.7% completion rate

The Short Message Service (“SMS”) transmission volumes in China have been growing since the turn of the century, increasing from 440.1 million messages in 2000 to 304.6 billion in 2005 (https://ibn.fm/DcpWq), and, more recently, 1.23 trillion in 2020, representing a 279,382% increase in just two decades. Although the number of messages sent dipped between 2013 and 2018, it eventually resurged, and the upward trajectory has not stopped since (https://ibn.fm/vG92d). It was during this resurgence period that FingerMotion (OTCQX: FNGR) entered the SMS enterprise market through its wholly owned subsidiary, JiuGe Information Technology (“JiuGe”), having acquired SMS infrastructure in early 2019 (https://ibn.fm/rKD6U). Notably, JiuGe had already landed recurring monthly contracts to send millions of SMS messages for enterprise clients in its first year of operation. Since then, the company has grown its clientele thanks to its solid performance. Just recently, for example, FingerMotion announced it had inked a new volume-based contract with China Mobile Fujian, a subsidiary of China Mobile. The new agreement follows JiuGe’s commitment to continuously improve its platform, resulting in positive customer response rates and distinguishing it from competitors. The deal is expected to grow FingerMotion’s gross margins for SMS by up to 30% in the current financial year (https://ibn.fm/dKotO). This SMS and MMS Services division generates the majority of the company’s revenues and also brings much higher margins than the Telecommunication Products & Services (“TPS”) division. Its formative business unit, TPS generates a tremendous amount of Gross Transaction Volume (“GTV”) but earns low revenues from commissions. Even so, these two divisions currently represent the only revenue-generating business units – the others are Big Data Insights (“Sapientus”) and Rich Communication Services (“RCS”) Platform Services. Despite being a low-margin business unit, however, FingerMotion considers the TPS division a crucial part of its overall business plan that sets a strong foundation for access to telecommunication companies and their users, integral to the operations of Sapientus (https://ibn.fm/vYJLo). Through PigeonHoles Integration System (“PIS”), FingerMotion’s proprietary universal exchange platform, the TPS division connects telecom service providers and online stores. PIS ensures that consumers can top up and recharge, purchase mobile phones, fulfill subscription plans, redeem loyalty points, and purchase data plans, all within a reliable and secure system that facilitates real-time reconciliation, efficient settlements, and simple integration for partners. “One of the challenges we solved with our PIS platform was integration. Each of the telecoms had their own interface, which was proprietary to them so that there wasn’t a single platform where you could get connected into the respective telecom ecosystem. We solved that and even made it easier for the major e-commerce platforms to access the telecoms,” commented Shen in a presentation during the 2021 Emerging Growth Conference (https://ibn.fm/Gf2tX). Shen further described how FingerMotion cemented its relationship with its telecom partners in a multistep process whose initial stages entailed collaborating with the companies and identifying what they needed. FNGR then utilized this knowledge, coupled with an innovative approach, to develop the reliable PIS platform capable of handling over 5000 transactions per minute, with a 99.7% completion rate. With this particular system, which the company is continually improving, FingerMotion has fundamentally differentiated itself from competitors, thereby wooing customers who are always looking for platforms with a high completion rate. Further, FNGR offered top-notch customer service and, through continuous innovation, also provided additional products. Lastly, the company measured its own success using metrics and parameters, such as the revenue per user, and rolled out new campaigns demonstrating how it could improve the figures. Focused on providing value to its clients, as well as continually improving its services through innovation, FingerMotion has differentiated its two revenue-generating business units from competitors. This approach has cemented its relationship with its existing clientele and is also bound to help it grow its revenues and client base. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Knightscope autonomous security robots (“ASRs”) are designed to use the latest advances in technology to help provide a sense of security for the company’s business clients nationwide
• The ASR robots’ capabilities range from recording with 360-degree high-definition night and day video capture to thermal imaging that is capable of triggering alerts to operators when a troubling anomaly is detected
• Knightscope has the backing of more than 28,000 investors and 4 major corporations raising over $90 million to build its groundbreaking technology from scratch
• The company is anticipating a public IPO at an undefined time in the future

The security upgrades at a Netherlands soccer stadium, recently completed, highlight the importance of having the best available technology as a partner in preventing or responding to crime within a business facility’s confines. “The images from the old cameras could no longer be used as legal evidence,” Goffert Stadium Manager Theo van Benthum told Security magazine (https://ibn.fm/ywGpV). “In matches with an increased risk of disturbances, the police come to us to watch and if they think that the camera footage cannot be used, this could have consequences for us. For example, we have to allow fewer visitors or certain competitions may no longer take place.” The autonomous security robot (“ASR”) developers at Knightscope are continually working to ensure their models employ a reputable standard of technological tools as part of their efforts to stave off and eliminate crime across the United States. The over-5-foot-tall K5 outdoor robot, for example, has advanced anomaly detection features that include 360-degree high-definition night and day video capture positioned at eye-level, live streaming and recorded high-definition video transmission, automatic license plate recognition, “parking meter”-type analysis of how long vehicles remain in a parking lot, time-stamped people detection with an accompanying alert system, thermal imaging with accompanying alerts, two-way communications and digital signal detection for sensitive areas such as a data center susceptible to rogue access. The company is in the process of developing the fifth generation of the K5, which is planned for initial release during 2022. Knightscope has recently announced a few new or renewed contracts with technology service providers involved in the K5’s latest upgrade, such as high-performance power module developer Vicor (https://ibn.fm/hjAHt). The private company’s ongoing fundraising efforts, including its recently completed Regulation A+ offering, have situated the company with the backing of over 28,000 investors and more than $90 million raised since its inception in 2013 and is actively working on a possible public listing. In the meantime, the American public continues to become more acquainted with Knightscope’s robots as they patrol client locations. The company’s blog notes that a Reno, Nev., casino has deployed one of Knightscope’s robot ASRs after learning of their use in California casinos (https://ibn.fm/ye6yu), and a news agency recently reported on the deployment of a Knightscope ASR at a Tucson community college campus (https://ibn.fm/I23Vm). “I’ve seen students and faculty following behind the robot videotaping it. I’ve seen people taking selfies with it,” Pima Community College Police Chief Harold “Buddy” Janes told the news agency. “It’s rather obvious that it’s associated with the police so it is a deterrent in the downtown area here. We have lots of foot traffic coming across our property so we want to make everybody feel safe and feel that environment. At all times.” Janes told the outlet that leasing the Knightscope ASR costs the department less than deploying a human officer and simply fulfills basic requirements for recording data and showing a police presence in the area. For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Parents’ satisfaction with their children’s education is slipping, according to a recent Gallup poll
• COVID-19 has taken a tremendous toll on an already poorly structured system, a system that Emaginos has a plan to fix
• Being first to market with a game-changing educational approach in a space where there is widespread dissatisfaction puts Emaginos in the driver’s seat

Parents’ satisfaction with their children’s education is slipping; in the last year the number dropped almost 10 percentage points, according to a recent Gallup poll (https://ibn.fm/l0LYr). The first company to offer a tested, proven actionable plan to transform and improve public schools rather than replace them, Emaginos Inc. is strongly positioned to make a difference in the education space. “Since Gallup began tracking this question annually in 1999, only about one in 10 U.S. adults report being completely satisfied with the quality of U.S. education,” the report stated. “The low point in overall satisfaction with the nation’s schools over the 21-year trend was 36% in 2000, when education was a key issue in the U.S. presidential election. The 53% high point in satisfaction was in 2004 as Republicans were overwhelmingly positive about the results of President George W. Bush’s ‘No Child Left Behind’ education reform law.” COVID-19 has taken a tremendous toll on an already poorly structured system, a system that the education experts at Emaginos have a plan to restructure and strengthen — without any additional costs. The company has carefully designed a model that utilizes existing funding, facilities, and staff to improve educational approaches and outcomes. In fact, in many instances, the Emaginos platform can actually save school districts money. Even more important, the Emaginos Discovery Learning System (“DLS”), is focused on engaging students by providing a customized education for every child and hands-on learning opportunities. “Emaginos considers every child as special and at risk – some at greater risk than others,” the company explains (https://ibn.fm/ZMP0C). “We deliver a customized education to each child based upon a continuous improvement model. Our students master the academic content and high performance skills without teaching to the test.” Being the first to market with a game-changing educational approach in a space where there is widespread dissatisfaction puts Emaginos in the driver’s seat. Educators, parents and investors looking to make a difference in education may be well advised to look at what Emaginos has to offer. Dedicated to transforming K-12 public schools to a model composed of integrated proven best practices, Emaginos opposes replacing public schools with charter schools or damaging public schools by draining resources through vouchers or school choice programs. Emaginos firmly believes in restoring the concept of the neighborhood schools as the center of the community. For more information, visit the company’s website at www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• Ideanomics recently reported $32.7 million in revenue and $10.8 million in gross profit for the three months ending March 31, 2021
• These Q1 2021 results represented a sharp increase compared to Q1 2020 results
• Ideanomics announced it has reached a definitive agreement to purchase 100% of US Hybrid
• The acquisition is set to bring synergistic benefits to both US Hybrid and Ideanomics Mobility companies
• Established in 1999, US Hybrid designs, manufactures, and markets electric powertrain components

On Monday, May 17, Ideanomics (NASDAQ: IDEX) released its Q1 2021 financials for the three months ending March 31, 2021. In what CEO Alf Poor described as an indication that Ideanomics is transforming dramatically quarter over quarter, the company reported impressive operating results compared to Q1 2020 results. According to a press release (https://ibn.fm/5h2BC) and the accompanying quarterly 10-Q report filing (https://ibn.fm/tuKcQ), Ideanomics reported $32.7 million in revenue for Q1 2021, compared to $378,000 reported in Q1 2020. Further, its gross profit grew from $44,000 in Q1 2020 to $10.8 million in Q1 2021. This robust growth demonstrates the vitality of Ideanomics’ business, as well as its ability to bounce back. The US accounted for $29.6 million or 90.6% of the total revenue, followed by China with $3.1 million (9.3%), and Malaysia with $7,000. In terms of revenues from products and services, Timios, Ideanomics’ title and escrow service, generated $27.6 million (84.4%), while WAVE, a company operating in the charging and batteries segment, accounted for 5.7% ($1.8 million). Ideanomics’ electric vehicle segment posted $3.0 million in revenues (9.2%), with the company also generating $197,000 from digital advertising and other services. “I am both pleased and proud to say that as it stands today, the company is the healthiest it has been in close to three years that I have been on board,” said Alf in the press statement accompanying the announcement. Later that day, Alf joined the Chief Financial Officer, Conor McCarthy, Chief Revenue Officer, Kristen Helsel, and SVP of Investor Relations, Tony Sklar, in hosting an earnings call. The company is making available a recording of this conference call. Meanwhile, Ideanomics recently demonstrated its continued commitment to look for new investments and buyouts in revenue-based opportunities when it announced it has reached an agreement to acquire 100% of privately held US Hybrid (https://ibn.fm/CHPHM). The acquisition, set to be paid with cash and stock considerations, will enable Ideanomics to use US Hybrid’s US-built technology in its EVs. On its part, Ideanomics will help US Hybrid scale its business operations as the soon-to-be wholly owned subsidiary continues to deliver services to its existing customers. Founded in 1999, US Hybrid designs, manufactures, and sells electric powertrain parts for electric, hybrid, and fuel cell medium and heavy-duty municipality vehicles, buses, specialty cars, and commercial trucks. The various powertrain components it designs and develops include integrated power conversion systems and integrated motor drives, motors and controllers, DC-DC boost converters, and distributed energy management systems. Being a reputable and reliable manufacturer, US Hybrid’s quality products are used in many trucks and buses developed by original equipment manufacturers (“OEMs”). It further boasts a global customer base drawn from both the private and public sectors; the company has forged long-term commercial relationships and delivered projects to clients in the commercial, defense and aerospace, and transit industries. US Hybrid’s focus on the medium and heavy-duty EV segment is bound to have synergistic benefits, given, for instance, that Medici Motor Works (“MMW”), one of Ideanomics’ wholly owned subsidiaries, develops electric specialty vehicles, trucks, buses, and vans for the North American market. Ideanomics considers the acquisition a stepping stone towards fulfilling its long-held objective of providing technologies and vehicles wholly made in America. “With decades of experience and credibility from deployments with reputable customers, US Hybrid will become an innovation engine for Ideanomics and provide strategic opportunities for clean technology applications across the zero-emissions transportation value chain, both now and in the future,” said Alf about the deal. “This combination of our businesses provides for a bright future in zero-emission transportation, where we continue to innovate for the future, while scaling our commercial products to meet the immediate demands of the industry,” stated US Hybrid CEO Dr. Gordon Abas Goodarzi, PhD, PE. Dr. Gordon hailed the acquisition as an opportunity that will enable the company to unlock the commercialization and sales potential of its products. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients
• GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once they are diagnosed, prompting research efforts to improve patients’ responses to therapeutic approaches
• A recent study found that the GBM patients most likely to succumb within a relatively short period could be identified with non-invasive MRI scans, allowing researchers to grant them priority in clinical trials
• Another recent study found patient responses could be improved simply by changing the time of day that therapy is administered to the morning
• CNS Pharmaceuticals’ lead drug candidate, Berubicin, showed promise in a small Phase 1 trial 15 years ago and now is being prepped for a larger Phase 2 trial
• Two other clinical trials are in development by sublicensee partner WPD Pharmaceuticals in Europe, including one for pediatric patients with malignant gliomas

Researchers’ recent successful efforts to identify a select set of brain cancer patients least likely to prolong survival when receiving standard treatment have been welcomed by the medical community amid efforts to develop better treatments and potential cures. The announcement by the Cimino lab at The University of Washington and Seattle’s Fred Hutchinson Cancer Research Center last month states a machine learning model has been developed that is “capable of identifying glioblastoma (‘GBM’) patients predisposed to poor survival from non-invasive MRI scans alone,” thus providing a simple means of routing the most needing patients to priority positions in clinical trials “because they are the patients whose first-line therapy is most likely to fail” (https://ibn.fm/NZgN1). The news follows on an announcement by Washington University School of Medicine in St. Louis that GBM patients may gain longer survival rates simply by changing what time of day they receive treatments (https://ibn.fm/YokbN). CNS Pharmaceuticals (NASDAQ: CNSP) is one of the companies working to produce a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of GBM patients. GBM is an illness that is nearly 100 percent fatal in patients just over a year after it’s diagnosed, and CNS Pharmaceuticals’ lead drug candidate, Berubicin (https://ibn.fm/up2fu), has been granted investigational new drug (“IND”) status after promising findings that Berubicin may generate better patient outcomes. Berubicin is a stand-out anthracycline therapy because of its novel apparent ability to cross the blood-brain barrier to combat neurological tumors. The drug was the subject of a Phase I trial some 15 years ago in which 44 percent of patients saw their disease stabilize or improve and one patient achieved cancer-free status that has resulted in length of survival currently far beyond standard expectations, with the most recent evaluation conducted in November of 2020. CNS recently announced it is beginning to enroll patients for its planned Phase 2 trial so the first patient is likely to be dosed in the near term. The Phase 2 trial will compare Berubicin’s response to the effectiveness of lomustine in 243 GBM patients at about 35 clinical sites in the United States (https://ibn.fm/3EjRq) and an additional 25 sites across Europe and Asia Pacific. The company’s timeline includes a similar Phase 2 clinical trial of Berubicin in Poland during the present quarter conducted by CNS’s sublicensee partner, WPD Pharmaceuticals. WPD is also preparing to start a clinical trial to determine Berubicin’s safe use in pediatric patients with malignant gliomas later in the year, which would be the first investigation of Berubicin for children with these brain cancers (https://ibn.fm/Z1Wu0). CNS’s recent update to its annual 10K filing with the U.S. Securities and Exchange Commission (“SEC”) notes that WPD’s sublicense requires it to use reasonable efforts to develop and commercialize the companies’ products in the European countries Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia (https://ibn.fm/OkVHf). “We expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials,” CNS CEO John Climaco said in a January podcast interview. “We have five employees at this company, so we are a tiny little shop. But we have an absolute powerhouse compound” (https://ibn.fm/xRjb1). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Sports concussions on the rise; with more children playing sports, it is becoming an important public health problem
• Quantitative EEG shows promise in identifying athletes with post-concussion impairments; for this, reusable EEG caps and mobile-based applications are helpful
• BRSF provides portable EEG devices that bring brain diagnostics to settings where it was previously impossible including off-site testing within sports

A recent article published by Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company operating in the brain diagnostics space, discusses how concussions or Traumatic brain injuries (“TBI”) are a significant risk for young athletes, quickly becoming an important public health issue as more and more children and teens are playing contact sports (https://ibn.fm/Jm5rT). TBI is a primary cause of death and lifelong disability in children and young adults in the United States. Centers for Disease Control and Prevention estimates that each year 1.5 million Americans sustain a TBI, leading to 50,000 deaths — one-third of all injury-related deaths — and causing long-term disability in up to 90,000 people (https://ibn.fm/F4VUm). Concussions result from head trauma in contact sports. Although they are usually minor and self-limiting, some can lead to significant long-term cognitive, physical, and psychosocial impairment. Unfortunately, at this moment, it is challenging to differentiate between the two effectively. Further compounding the prognostic challenge is that the risk of long-term complications from concussion increases as the number of concussive episodes per patient increases. CT is the most commonly used imaging procedure. Although it is quick, widely available, and relatively cost-effective, it is not effective when conducting a post-concussion examination. MRIs and neuropsychologic testing are somewhat more effective but are time-consuming. Novel imaging techniques such as PET scan or functional MRI and specific biomarkers may prove useful, but work in this area is still ongoing. What about EEG, a technology that has been around for around 100 years? Traditional EEG has a long history of attempting to become the gold standard for concussion diagnostics, but it never emerged as the first-line diagnostic tool. Still, can novel, sophisticated technologies such as quantitative EEG help turn the tables when it comes to effective diagnostics and prognostics of post-concussion patient outcomes? Indeed, multiple studies and — even more convincingly systematic literature review of studies — show promise in revealing patterns of quantitative EEG abnormality that correlate with acute, subacute, and chronic concussions. This technique may potentially help determine the severity of trauma. The Institute of Medicine (“IOM”) Committee on Sports-Related Concussions in Youth states that QEEG “can detect differences in performance and neural responses in concussed versus non-concussed student-athletes in high school and college even when behavior measures fail to do so” (https://ibn.fm/V6qTA). While it may still be challenging to reliably decipher EEG or QEEG differences between individuals with a concussion and healthy controls, the value of these procedures may lie in pre-and post-concussion comparisons where readings. Here, pre-trauma readings would be compared to post-trauma readings of the same patient. EEG electrode caps and mobile phone applications could enable QEEG screening for athletes as part of their preseason health check. With portable devices, sideline-based concussion assessment could help identify indicators consistent with acute TBI and concussion during the game. Portable EEG diagnostics is precisely the space that BSFR aims to revolutionize. With the Company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), it is now possible to conduct quick and reliable EEG testing in minutes by any healthcare worker, not only specialized neurological technicians. These powerful yet affordable solutions bring brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing, including off-site testing within sports to diagnose concussions and other head trauma that occur on the field without transporting a patient to the hospital. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Friendable and Santo Blockchain Labs and Mining Corp. working together for the development of global entertainment and musical artist-driven non-fungible tokens, along with the development of a “Fanpasscrypto” marketplace
• Each NFT is a unique opportunity for a new revenue stream for artists and the two companies
• While the Union of Musicians and Allied Workers (“UMAW”) is bringing grievances against streaming platforms like Spotify and Apple Music, Fan Pass continues to seek and incorporate ways for artists to receive revenue

A non-fungible token (“NFT”) is not a form of cryptocurrency (or a form of monetary value), but represents a digital certification of the value of an item that lives on the blockchain. NFTs create digital contracts, proof of ownership, proof of authenticity, certification, also any other items and business rules that are related to the item, attaching to them through its lifespan – defining what it is and the value it holds. Each NFT is unique based on the information stored in the token’s metadata, including token ID that points to the artwork, image, web domain, or another valuable digital resource. This new form of digital ownership is being leveraged by mobile technology and marketing company Friendable (OTC: FDBL) to enhance its Fan Pass platform offering to artist members and their fans. Recently, Friendable has signed a Letter of Intent (“LOI”) with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) for the development of global entertainment and musical artist-driven NFTs, as well as the development of the “Fanpasscrypto” marketplace. Each NFT created is a unique opportunity for a new revenue stream for artists and the two companies. Friendable’s NFTs will be unique and may represent both digital and/or augmented reality images. The NFTs themselves may be images of the entertainers or customized to offer exclusive merchandising and interactions. There are multiple ways for the company to monetize, which may also open the doors for opportunities with brand sponsors and retail brands. “It’s been three long years since the inception of our flagship crypto code SKULLYS. We are proud to bring over 100,000 lines of unique code to the outstanding team over at Fan Pass. With the rise of blockchain and NFT technology, the future is only limited by our imagination,” Santo Blockchain Labs CEO Frank Yglesias said about the deal (https://ibn.fm/9sxbB). SKULLYS are a line of reward-based digital collectibles found on the blockchain that uses a specially embedded “pirate code” proprietary to the Santo – A.R.R. (Accept, Relinquish, Reward). Even with the upcoming NFT offering, Fan Pass is still finding ways to reward and incentivize artists, while other streaming companies are facing complaints over their revenue structures. Platforms like Apple and Spotify are taking heat because of how artist royalty distribution is handled. When monthly fees are paid, they are distributed starting with the most popular artist’s royalties and trickling down the ecosystem. Even with the push back from the Union of Musicians and Allied Workers (“UMAW”), there is skepticism that the streaming industry can be shaped to conform to every artist’s liking. Fan Pass has a payment structure for artists that allows them to take a cut of the monthly subscription costs, but also additional forms of revenue, including ticket sales for VIP events, monthly contests, merchandise, and NFTs in the future. Each month, Fan Pass also rewards the top artists and those who are new to the platform. These are only the beginning of what artists will be able to do on the Fan Pass platform as a means of earning a living in the post-pandemic world. Fan Pass also offers premium services that help new and existing artists with merchandise, marketing, and other foundational attributes of their craft. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Musicians have had to find ways to adapt their crowd-based revenue streams to the restrictive conditions of the ongoing pandemic
• Several artists have turned to Internet-accessible events to keep the paychecks coming in, adapting their royalty models to those conditions
• To show musicians there may be a different way to profit from their royalties BAND Royalty has acquired the performance royalties of songs performed by Justin Timberlake, Timbaland, Rihanna, Beyonce, Cher, Demi Lovato and other multi -platinum performers and  are developing a way to connect these royalties to collectible digital art, NFTs, that can be used in a unique DeFi product that lets NFT holders access a piece of the music royalty revenues.
• The NFTs brought in the Ethereum equivalent of over $700,000 during a presale May 5. On May 17^th, 2021 Band Royalty released the first ever Music NFT only platform on their website. Available for sale are the remaining 2000 NFTs, starting at 1 ETH, directly on their website.

Among the harmful effects of the pandemic on economies worldwide is the shutdown of public performance venues such as concert stadiums where artists have the ultimate opportunity to connect with fans and influence not only sales, but some measure of cultural conception. A study by global entertainment ticketing company Live Nation in 2018, prior to the pandemic’s outbreak, found that among respondents in the United States, Canada, Mexico, Brazil, United Kingdom, Germany, France, Scandinavia, China, Japan and Australia, 72 percent of Gen Z / Millennial audiences have driven over 100 miles to go to a live music event, two-thirds of Gen X, Y, and Z attend at least one concert or festival each year, that a majority of them go to multiple such events each year, and that 78 percent reported feeling high emotional intensity. Overall, the respondents rated their musical preferences as having a greater import on defining them as a person than their hometown, politics, race or religion (https://ibn.fm/PgD6d). During the course of the pandemic, a number of artists have adapted by performing goodwill as well as for-profit events online in an effort to adapt to the health code restrictions imposed by governments around the globe, remain on fans’ radars and keep revenues flowing (https://ibn.fm/74885). The efforts highlight the importance of tailoring the royalty payment model to ever-changing circumstances in the industry. BAND Royalty, a company devoted to music industry innovations wants to use NFTs and DeFi principles that increase transparency and engagement between artists and their fans.  They have history in the music monetization sector recently with its non-fungible token (“NFT”) product that pairs premier works of digital art with DeFi access to revenue streams from music performed by select artists including Beyoncé, Justin Timberlake, Rihanna, will.i.am and Jay-Z. NFTs are comparable to collectibles that fans can buy, trade or simply store and admire, whose potential monetary value may increase over time according to their rarity and persistent appeal. BAND’s model revolutionizes the DeFi sector by making the NFTs stakeable in royalty pools that effectively allow NFT holders to receive a percentage of the revenue from various artists’ works. In a pre-sale a couple hundred BAND NFT collectibles sold for a combined cryptocurrency value of over $700,000 in Ethereum equivalence to select buyers on May 5. With the unsold NFT collectibles becoming available on Band Royalty’s first ever Music NFT marketplace, on May 17 for general public purchase on a first-come, first-served basis (https://ibn.fm/1Ajvn). Additional series of BAND NFT collectibles and a band token launch will be rolled out later this year. The staked NFTs are granted access to revenues from a shared percentage of the songwriter’s “writer rights,” which, when paired with the publisher’s share, comprise the primary two components of music intellectual property (“IP”) rights and royalties (https://ibn.fm/6EwXq). Under BAND’s royalty shares model, the NFT holder can choose whether to pit the value of the NFT on a temporary basis against potential royalties that might be derived from a choice of three channels — publishing of a musical selection, public and mechanical performances of the musical selection, or visual media synchronization of the selection such as its appearance in a movie, video game or advertisement. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND